Literature DB >> 17213404

A new era of unapproved drugs: the case of Abigail Alliance v Von Eschenbach.

Peter D Jacobson1, Wendy E Parmet.   

Abstract

Mesh：

Substances：

Year:  2007        PMID： 17213404     DOI： 10.1001/jama.297.2.205

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  13 in total

1.  Preemption, tort reform, and pharmaceutical claims: Part two: Has the Food and Drug Administration shown it is solely responsible for the protection of patients? Can it do so? Will it do so?

Authors:  Russell G Thornton
Journal:  Proc (Bayl Univ Med Cent)       Date:  2008-01

2.  Uncertainty and equipoise: at interplay between epistemology, decision making and ethics.

Authors:  Benjamin Djulbegovic
Journal:  Am J Med Sci       Date:  2011-10       Impact factor: 2.378

3.  The courts and public health: caught in a pincer movement.

Authors:  Wendy E Parmet; Peter D Jacobson
Journal:  Am J Public Health       Date:  2014-01-16       Impact factor: 9.308

4.  Rigorous Clinical Trial Design in Public Health Emergencies Is Essential.

Authors:  Susan S Ellenberg; Gerald T Keusch; Abdel G Babiker; Kathryn M Edwards; Roger J Lewis; Jens D Lundgren; Charles D Wells; Fred Wabwire-Mangen; Keith P W J McAdam
Journal:  Clin Infect Dis       Date:  2018-04-17       Impact factor: 9.079

5.  Scientific research and the public trust.

Authors:  David B Resnik
Journal:  Sci Eng Ethics       Date:  2010-08-29       Impact factor: 3.525

6.  Recommendations to Facilitate Expanded Access to Investigational Therapies for Seriously Ill Patients.

Authors:  Rebecca N Jerome; Terri L Edwards; Haley C Boswell; Gordon R Bernard; Paul A Harris; Jill M Pulley
Journal:  Acad Med       Date:  2016-03       Impact factor: 6.893

7.  When is it rational to participate in a clinical trial? A game theory approach incorporating trust, regret and guilt.

Authors:  Benjamin Djulbegovic; Iztok Hozo
Journal:  BMC Med Res Methodol       Date:  2012-06-22       Impact factor: 4.615

8.  Risks and benefits of unapproved disease-modifying treatments for neurodegenerative disease.

Authors:  Aden C Feustel; Amanda MacPherson; Dean A Fergusson; Karl Kieburtz; Jonathan Kimmelman
Journal:  Neurology       Date:  2019-12-02       Impact factor: 9.910

9.  Going "social" to access experimental and potentially life-saving treatment: an assessment of the policy and online patient advocacy environment for expanded access.

Authors:  Tim K Mackey; Virginia J Schoenfeld
Journal:  BMC Med       Date:  2016-02-02       Impact factor: 8.775

10.  Expanded Access Programs: Ethical and Practical Considerations for Biopharmaceutical Sponsors.

Authors:  Mitchell Klopfenstein; Luann E Van Campen; Timothy Garnett
Journal:  Ther Innov Regul Sci       Date:  2015-04-02       Impact factor: 1.778
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.